Production (Stage)
BioCryst Pharmaceuticals, Inc.
BCRX
$10.59
$0.201.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -53.47M | -88.88M | -123.82M | -145.93M | -208.59M |
| Total Depreciation and Amortization | 3.04M | 3.01M | 2.57M | 2.68M | 2.77M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 125.47M | 121.13M | 123.37M | 124.30M | 157.77M |
| Change in Net Operating Assets | -100.89M | -87.28M | -57.85M | -64.92M | -53.27M |
| Cash from Operations | -25.85M | -52.02M | -55.73M | -83.87M | -101.31M |
| Capital Expenditure | -1.03M | -1.12M | -1.00M | -1.93M | -2.24M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.96M | 53.72M | 7.33M | 22.88M | 6.61M |
| Cash from Investing | 50.93M | 52.59M | 6.32M | 20.95M | 4.37M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 300.00M |
| Total Debt Repaid | -1.83M | -1.70M | -2.51M | -1.96M | -242.01M |
| Issuance of Common Stock | 4.76M | 4.06M | 4.22M | 3.62M | 5.30M |
| Repurchase of Common Stock | -581.00K | -581.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.54M | -7.54M | -6.62M | -6.62M | -36.93M |
| Cash from Financing | -4.18M | -5.76M | -4.91M | -4.96M | 26.36M |
| Foreign Exchange rate Adjustments | -145.00K | -936.00K | 890.00K | 292.00K | 118.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.75M | -6.12M | -53.43M | -67.58M | -70.47M |